Business
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows: Conference: Piper Sandler 37th Annual Healthcare ConferenceDate/Time: Wednesday, December 3, 2025 at 2:30
About this update from Altimmune, Inc.
GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 37 th Annual Healthcare Conference. Details are as follows: Conference: Piper Sandler 37 th Annual Healthcare Conference Date/Time: Wednesday, December 3, 2025 at 2:30 p.m. ET The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 [email protected] Media Contact: Savannah Valade Real Chemistry [email protected] This press release was published by a CLEAR® Verified individual.